-
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7. -
Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K, Nicolaides KH.
BJOG 2003;110:276-80. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:219-25. -
First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH.
Hum Reprod 2001;16:1501-4. -
Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype.
Ghi T, Huggon IC, Zosmer N, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:610-4. -
Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study.
Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K.
Lancet 2001;358:1665-7. -
First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status.
Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:852-3. -
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2000;20:683-4. -
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:673-5. -
Nuchal translucency as a marker of congenital heart disease.
Perdu M, Hyett JA, Sharland G, Snijders RS, Nicolaides KH.
Contracept Fertil Sex 1999;27:I-V. -
Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks.
Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:307-10. -
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study.
Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH.
BMJ 1999;318:81-5. -
Collagen type VI gene expression in the skin of trisomy 21 fetuses.
von Kaisenberg CS, Brand-Saberi B, Christ B, Vallian S, Farzaneh F, Nicolaides KH.
Obstet Gynecol 1998;91:319-23. -
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation.
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH.
Lancet 1998;352:343-6. -
Cardiac expression of sarcoplasmic reticulum calcium ATPase in fetuses with trisomy 21 and trisomy 18 presenting with nuchal translucency.
von Kaisenberg CS, Huggon I, Hyett JA, Farzaneh F, Nicolaides KH.
Fetal Diagn Ther 1997:12:270-3. -
Down's syndrome screening with nuchal translucency.
Nicolaides KH, Sebire NJ, Snijders RJ.
Lancet 1997;349:438. -
Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects.
Hyett JA, Perdu M, Sharland GK, Snijders RSM, Nicolaides KH.
Ultrasound Obstet Gynecol 1997;10:242-6.